These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

894 related items for PubMed ID: 31575518

  • 1. Safety of Paclitaxel-Coated Balloon Angioplasty for Femoropopliteal Peripheral Artery Disease.
    Ouriel K, Adelman MA, Rosenfield K, Scheinert D, Brodmann M, Peña C, Geraghty P, Lee A, White R, Clair DG.
    JACC Cardiovasc Interv; 2019 Dec 23; 12(24):2515-2524. PubMed ID: 31575518
    [Abstract] [Full Text] [Related]

  • 2. German Center Subanalysis of the LEVANT 2 Global Randomized Study of the Lutonix Drug-Coated Balloon in the Treatment of Femoropopliteal Occlusive Disease.
    Scheinert D, Schmidt A, Zeller T, Müller-Hülsbeck S, Sixt S, Schröder H, Weiss N, Ketelsen D, Ricke J, Steiner S, Rosenfield K.
    J Endovasc Ther; 2016 Jun 23; 23(3):409-16. PubMed ID: 27117972
    [Abstract] [Full Text] [Related]

  • 3. The LEVANT I (Lutonix paclitaxel-coated balloon for the prevention of femoropopliteal restenosis) trial for femoropopliteal revascularization: first-in-human randomized trial of low-dose drug-coated balloon versus uncoated balloon angioplasty.
    Scheinert D, Duda S, Zeller T, Krankenberg H, Ricke J, Bosiers M, Tepe G, Naisbitt S, Rosenfield K.
    JACC Cardiovasc Interv; 2014 Jan 23; 7(1):10-9. PubMed ID: 24456716
    [Abstract] [Full Text] [Related]

  • 4. Evaluation of Mortality Following Paclitaxel Drug-Coated Balloon Angioplasty of Femoropopliteal Lesions in the Real World.
    Böhme T, Noory E, Beschorner U, Jacques B, Bürgelin K, Macharzina R, Gebauer E, Cheung F, Lechner P, Nührenberg T, Zeller T.
    JACC Cardiovasc Interv; 2020 Sep 14; 13(17):2052-2061. PubMed ID: 32593696
    [Abstract] [Full Text] [Related]

  • 5. Long-Term Clinical Effectiveness of a Drug-Coated Balloon for the Treatment of Femoropopliteal Lesions.
    Laird JA, Schneider PA, Jaff MR, Brodmann M, Zeller T, Metzger DC, Krishnan P, Scheinert D, Micari A, Wang H, Masters M, Tepe G.
    Circ Cardiovasc Interv; 2019 Jun 14; 12(6):e007702. PubMed ID: 31195825
    [Abstract] [Full Text] [Related]

  • 6. Paclitaxel-Eluting Balloon Versus Standard Balloon Angioplasty in In-Stent Restenosis of the Superficial Femoral and Proximal Popliteal Artery: 1-Year Results of the PACUBA Trial.
    Kinstner CM, Lammer J, Willfort-Ehringer A, Matzek W, Gschwandtner M, Javor D, Funovics M, Schoder M, Koppensteiner R, Loewe C, Ristl R, Wolf F.
    JACC Cardiovasc Interv; 2016 Jul 11; 9(13):1386-92. PubMed ID: 27388828
    [Abstract] [Full Text] [Related]

  • 7. 12-Month Results From the First-in-Human Randomized Study of the Ranger Paclitaxel-Coated Balloon for Femoropopliteal Treatment.
    Steiner S, Willfort-Ehringer A, Sievert H, Geist V, Lichtenberg M, Del Giudice C, Sauguet A, Diaz-Cartelle J, Marx C, Ströbel A, Schult I, Scheinert D, RANGER SFA Investigators.
    JACC Cardiovasc Interv; 2018 May 28; 11(10):934-941. PubMed ID: 29730375
    [Abstract] [Full Text] [Related]

  • 8. Drug-Coated Balloon Angioplasty Compared With Uncoated Balloons in the Treatment of 200 Chinese Patients With Severe Femoropopliteal Lesions: 24-Month Results of AcoArt I.
    Xu Y, Jia X, Zhang J, Zhuang B, Fu W, Wu D, Wang F, Zhao Y, Guo P, Bi W, Wang S, Guo W.
    JACC Cardiovasc Interv; 2018 Dec 10; 11(23):2347-2353. PubMed ID: 30448170
    [Abstract] [Full Text] [Related]

  • 9. Paclitaxel-Coated Balloon vs Uncoated Balloon Angioplasty for Treatment of In-Stent Restenosis in the Superficial Femoral and Popliteal Arteries: The COPA CABANA Trial.
    Tepe G, Schroeder H, Albrecht T, Reimer P, Diehm N, Baeriswyl JL, Brechtel K, Speck U, Zeller T.
    J Endovasc Ther; 2020 Apr 10; 27(2):276-286. PubMed ID: 32096451
    [Abstract] [Full Text] [Related]

  • 10. Six-Month Results From the Initial Randomized Study of the Ranger Paclitaxel-Coated Balloon in the Femoropopliteal Segment.
    Bausback Y, Willfort-Ehringer A, Sievert H, Geist V, Lichtenberg M, Del Giudice C, Sauguet A, Diaz-Cartelle J, Marx C, Ströbel A, Schult I, Scheinert D, RANGER SFA Investigators.
    J Endovasc Ther; 2017 Aug 10; 24(4):459-467. PubMed ID: 28558502
    [Abstract] [Full Text] [Related]

  • 11. Systematic review and updated meta-analysis of the use of drug-coated balloon angioplasty versus plain old balloon angioplasty for femoropopliteal arterial disease.
    Caradu C, Lakhlifi E, Colacchio EC, Midy D, Bérard X, Poirier M, Ducasse E.
    J Vasc Surg; 2019 Sep 10; 70(3):981-995.e10. PubMed ID: 31126769
    [Abstract] [Full Text] [Related]

  • 12. Treatment Effect of Drug-Coated Balloons Is Durable to 3 Years in the Femoropopliteal Arteries: Long-Term Results of the IN.PACT SFA Randomized Trial.
    Schneider PA, Laird JR, Tepe G, Brodmann M, Zeller T, Scheinert D, Metzger C, Micari A, Sachar R, Jaff MR, Wang H, Hasenbank MS, Krishnan P, IN.PACT SFA Trial Investigators.
    Circ Cardiovasc Interv; 2018 Jan 10; 11(1):e005891. PubMed ID: 29326153
    [Abstract] [Full Text] [Related]

  • 13. Drug-Coated Balloon vs Standard Percutaneous Transluminal Angioplasty for the Treatment of Atherosclerotic Lesions in the Superficial Femoral and Proximal Popliteal Arteries: One-Year Results of the MDT-2113 SFA Japan Randomized Trial.
    Iida O, Soga Y, Urasawa K, Saito S, Jaff MR, Wang H, Ookubo H, Yokoi H, MDT-2113 SFA Japan Investigators.
    J Endovasc Ther; 2018 Feb 10; 25(1):109-117. PubMed ID: 29264999
    [Abstract] [Full Text] [Related]

  • 14. Mortality After Paclitaxel Coated Balloon Angioplasty and Stenting of Superficial Femoral and Popliteal Artery in the Vascular Quality Initiative.
    Bertges DJ, Sedrakyan A, Sun T, Eslami MH, Schermerhorn M, Goodney PP, Beck AW, Cronenwett JL, Eldrup-Jorgensen J.
    Circ Cardiovasc Interv; 2020 Feb 10; 13(2):e008528. PubMed ID: 32069110
    [Abstract] [Full Text] [Related]

  • 15. A Pilot Study of Femoropopliteal Artery Revascularisation with a Low Dose Paclitaxel Coated Balloon: Is Predilatation Necessary?
    Schroeder H, Meyer DR, Lux B, Ruecker F, Martorana M, Miller LE, Duda S.
    Eur J Vasc Endovasc Surg; 2017 Sep 10; 54(3):348-355. PubMed ID: 28778456
    [Abstract] [Full Text] [Related]

  • 16. Drug-Coated Balloon Versus Plain Balloon Angioplasty for the Treatment of Femoropopliteal Artery Disease: An Updated Systematic Review and Meta-Analysis of Randomized Clinical Trials.
    Giacoppo D, Cassese S, Harada Y, Colleran R, Michel J, Fusaro M, Kastrati A, Byrne RA.
    JACC Cardiovasc Interv; 2016 Aug 22; 9(16):1731-42. PubMed ID: 27539695
    [Abstract] [Full Text] [Related]

  • 17. Cost-Effectiveness of Endovascular Femoropopliteal Intervention Using Drug-Coated Balloons Versus Standard Percutaneous Transluminal Angioplasty: Results From the IN.PACT SFA II Trial.
    Salisbury AC, Li H, Vilain KR, Jaff MR, Schneider PA, Laird JR, Cohen DJ.
    JACC Cardiovasc Interv; 2016 Nov 28; 9(22):2343-2352. PubMed ID: 27884360
    [Abstract] [Full Text] [Related]

  • 18. The 24-Month Results of the Lutonix Global SFA Registry: Worldwide Experience With Lutonix Drug-Coated Balloon.
    Thieme M, Von Bilderling P, Paetzel C, Karnabatidis D, Perez Delgado J, Lichtenberg M, Lutonix Global SFA Registry Investigators.
    JACC Cardiovasc Interv; 2017 Aug 28; 10(16):1682-1690. PubMed ID: 28780030
    [Abstract] [Full Text] [Related]

  • 19. Drug-coated balloons to improve femoropopliteal artery patency: Rationale and design of the LEVANT 2 trial.
    Jaff MR, Rosenfield K, Scheinert D, Rocha-Singh K, Benenati J, Nehler M, White CJ.
    Am Heart J; 2015 Apr 28; 169(4):479-85. PubMed ID: 25819854
    [Abstract] [Full Text] [Related]

  • 20. One-Year Clinical Outcomes of the Legflow Drug-Coated Balloon for the Treatment of Femoropopliteal Occlusions Registry.
    Stabile E, Gerardi D, Magliulo F, Zhelev D, Chervenkoff V, Taeymans K, Kotasov D, Goverde P, Giugliano G, Trimarco B, Esposito G.
    J Endovasc Ther; 2019 Feb 28; 26(1):26-30. PubMed ID: 30760132
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 45.